If you paid or provided reimbursement for some or all of the purchase price of Branded or authorized generic EpiPens for the purpose of consumption, and not resale, insureds, plan participants, employees, or beneficiaries, at any time between August 24, 2011, and November 1, 2020, and did not exclude yourself from the Class during the initial notice period you may be entitled to a portion of the $345 Million recovered in Class Action Settlements.
Status: Representing Clients (Deadline 11/12/21)